Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia

Current Neurovascular Research

Volumn 8, Issue 3, 2011, Pages 183-189

  Anghel, Andrei ^a   Taranu, Georgel ^b   Seclaman, Edward ^a   Rata, Andreea ^b   Tamas, Liviu ^a   Moldovan, Horatiu ^c   Ursoniu, Sorin ^a   Samoila, Corina ^a   Ionac, Mihai ^b   Popa Wagner, Aurel ^d,e  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Emergency County Hospital Timisoara ^*  (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^e UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

Critical limb ischemia; Gene therapy; HGF; VEGF

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRONE; GENE THERAPY AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENTOXIFYLLINE; PLACEBO; ROSUVASTATIN; SCATTER FACTOR; TRAMADOL; VASCULOTROPIN;

ADULT; AGED; ANAPHYLACTIC SHOCK; ANGIOGENIC GENE THERAPY; ANGIOGRAPHY; ANKLE BRACHIAL INDEX; ARTICLE; BUERGER DISEASE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FEVER; HEADACHE; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE DISCOLORATION; INJECTION SITE SWELLING; LEG AMPUTATION; LEG ISCHEMIA; LEG PAIN; MALE; MORTALITY; OUTCOME ASSESSMENT; PLASMID; PRIORITY JOURNAL; RISK ASSESSMENT; SHIVERING; WALKING;

EID: 80051517366     PISSN: 15672026     EISSN: 18755739     Source Type: Journal    
DOI: 10.2174/156720211796558050     Document Type: Article

References (24)

1. Diehm C, Diehm N. Non-invasive treatment of critical limb ischemia. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 241-7. (Pubitemid 39162415)
2. Orduna Gonzalez MJ, Lopez Caballo C, Camblor Suarez E, et al. Treatment of epidural pain in peripheral vascular ischemia. Rev Soc Esp Dolor 2009; 16: 101-11.
3. Novo S, Coppola G, Milio G. Critical Limb Ischemia: Definition and Natural History. Curr Drug Targets Cardiovasc Haematol Disord 2004; 4: 219-25. (Pubitemid 39162412)
4. Bull M. Peripheral Arterial Disease - The Forgotten Risk Factor. Prac Nurse 2005; 30: 4.
5. TASC II - Inter-Society Consensus for the Management of Peripheral Arterial Disease. Eur J Vasc Endovasc Surg 2007; 33(Suppl 1): S1-S70.
6. Rufollo AJ, Romano M, Ciapponi A. Prostanoids for critical limb ischemia. Cochrane Database of Systematic Reviews 2010; CD006544.
7. Anghel A, Mut-Vitcu B, Savu L, et al. Clinical improvement after treatment with VEGF165 in patients with severe chronic lower limb ischaemia. Genomic Med 2007; 1: 47-55. (Pubitemid 47319598)
8. Gerritsen ME. HGF and VEGF: a dynamic duo. Circ Res 2005; 96: 272-3. (Pubitemid 40279899)
9. Isner JM, Pieczek A, Schainfield R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-74. (Pubitemid 26261511)
10. Isner JM, Ropper A, Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001; 12: 1593-94.
11. Rajagopalan S, Shah M, Luciano A, et al. Adenovirus-mediated gene transfer of VEGF121 improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753-55. (Pubitemid 32762670)
12. Shyu KG, Chang H, Wang BW, et al. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischaemia. Am J Med 2003; 114: 85-92. (Pubitemid 36183588)
13. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin- 1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6: 460-63. (Pubitemid 30208166)
14. Dantz D, Bewersdorf J, Fruehwald-Schultes B, et al. Vascular endothelial growth factor: a novel endocrine defensive response to hypoglycemia. J Clin Endocr Metab 2002; 87: 835-40. (Pubitemid 34158260)
15. Helmlinger G, Endo M, Ferrara N, et al. Formation of endothelial cell networks. Nature 2000; 405: 139-41.
16. Tomita N, Morishita R, Taniyama Y, et al. Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003; 107: 1411-17. (Pubitemid 36350741)
17. Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 2004; 44: 203-09. (Pubitemid 39014240)
18. Powell RJ, Simons M, Mendelsohn FO, et al. Results of a doubleblind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation 2008; 118: 58-65.
19. Shigematsu H, Yasuda K, Iwai T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther 2010; 17: 1152-61.
20. Medina J, Caveda L, Sanz-Cameno P, et al. Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis C-associated neoangiogenesis. J Hepatol 2003; 38: 660-67. (Pubitemid 36560652)
21. van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor: the case for paracrine amplification of angiogenesis. Circulation 1998; 97: 381-90. (Pubitemid 28074339)
22. Cimpean AM, Seclaman E, Ceausu R, et al. VEGF-A/HGF induce Prox-1 expression in the chick embryo chorioallantoic membrane lymphatic vasculature. Clin Exp Med 2009; 10: 169-72.
23. Rajagopalan S, Olin J, Deitcher S, et al. Use of a constitutively active Hipoxia-Inducible Factor-1α transgene as a therapeutic strategy in no-option critical limb ischemia patients. Circulation 2007; 115: 1234-43. (Pubitemid 46594767)
24. Perrin LA, June JE, Rosebury W, et al. Increased revascularization efficacy after administration of an adenovirus encoding VEGF121. Gene Ther 2004; 11: 512-21. (Pubitemid 38443518)